TECHNIVIE

PeakSM

ombitasvir; paritaprevir; ritonavir

AbbVie
NDAORALTABLETPriority Review
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Apr 13, 2032
74 months away
Patent Expiry
Apr 13, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
8642538
Sep 10, 2029
SubstanceProduct
U-1638
9006387
Jun 10, 2030
U-1687
9044480
Apr 10, 2031
U-1638
8420596
Apr 10, 2031
SubstanceProduct
—
8686026
Jun 9, 2031
Product
—
Company
AbbVie
AbbVie
NORTH CHICAGO, IL
1495 open jobs
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers